PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
31 août 2021 04h08 HE
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
04 août 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Global $15.1 Bn Immuno-oncology Clinical Trials Market to 2028
30 juil. 2021 07h23 HE
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design...
Global Oncology Based In-Vivo CRO Markets, 2021-2027: Focus on Solid Tumors, Blood Cancer, Other Indications
27 juil. 2021 08h08 HE
|
Research and Markets
Dublin, July 27, 2021 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Oncology...
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
26 juil. 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
03 août 2020 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors
07 juil. 2020 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
09 janv. 2020 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
04 nov. 2019 01h30 HE
|
Erytech Pharma S.A.
Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 ...
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
23 oct. 2018 09h13 HE
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based...